CVS Health Co. (NYSE:CVS) Shares Sold by Cobblestone Capital Advisors LLC NY

Cobblestone Capital Advisors LLC NY decreased its position in shares of CVS Health Co. (NYSE:CVS - Free Report) by 14.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 114,927 shares of the pharmacy operator's stock after selling 18,921 shares during the quarter. Cobblestone Capital Advisors LLC NY's holdings in CVS Health were worth $5,159,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Assetmark Inc. raised its holdings in CVS Health by 9.7% in the 3rd quarter. Assetmark Inc. now owns 410,001 shares of the pharmacy operator's stock valued at $25,781,000 after acquiring an additional 36,132 shares during the last quarter. TD Private Client Wealth LLC raised its holdings in CVS Health by 28.7% in the 3rd quarter. TD Private Client Wealth LLC now owns 46,938 shares of the pharmacy operator's stock valued at $2,951,000 after acquiring an additional 10,465 shares during the last quarter. Principal Financial Group Inc. raised its holdings in CVS Health by 4.8% in the 3rd quarter. Principal Financial Group Inc. now owns 1,434,476 shares of the pharmacy operator's stock valued at $90,200,000 after acquiring an additional 66,244 shares during the last quarter. Sompo Asset Management Co. Ltd. raised its holdings in CVS Health by 8.4% in the 3rd quarter. Sompo Asset Management Co. Ltd. now owns 134,523 shares of the pharmacy operator's stock valued at $8,459,000 after acquiring an additional 10,453 shares during the last quarter. Finally, Hall Laurie J Trustee raised its holdings in CVS Health by 25,484.4% in the 4th quarter. Hall Laurie J Trustee now owns 11,513 shares of the pharmacy operator's stock valued at $517,000 after acquiring an additional 11,468 shares during the last quarter. Hedge funds and other institutional investors own 80.66% of the company's stock.

CVS Health Stock Down 1.4 %

CVS Health stock traded down $0.90 during trading on Monday, reaching $64.82. 7,077,932 shares of the company's stock were exchanged, compared to its average volume of 12,413,927. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. The company's 50-day moving average is $54.74 and its two-hundred day moving average is $56.53. The firm has a market cap of $81.72 billion, a price-to-earnings ratio of 17.71, a PEG ratio of 0.98 and a beta of 0.61. CVS Health Co. has a 52-week low of $43.56 and a 52-week high of $80.75.

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, beating analysts' consensus estimates of $0.89 by $0.30. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. On average, analysts predict that CVS Health Co. will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Thursday, January 23rd were given a $0.665 dividend. The ex-dividend date of this dividend was Thursday, January 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 4.10%. CVS Health's payout ratio is currently 72.68%.

Insider Buying and Selling at CVS Health

In other news, Director Michael F. Mahoney acquired 30,000 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was bought at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the transaction, the director now directly owns 39,356 shares in the company, valued at approximately $2,625,045.20. This represents a 320.65 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.24% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research analysts have weighed in on CVS shares. TD Cowen boosted their price target on CVS Health from $73.00 to $80.00 and gave the company a "buy" rating in a report on Monday, November 25th. Evercore ISI upped their price objective on CVS Health from $60.00 to $65.00 and gave the stock an "outperform" rating in a report on Monday, January 27th. Leerink Partners upgraded CVS Health from a "market perform" rating to an "outperform" rating and upped their price objective for the stock from $55.00 to $75.00 in a report on Thursday, February 13th. Leerink Partnrs upgraded CVS Health from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 12th. Finally, Barclays upped their price objective on CVS Health from $71.00 to $73.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, CVS Health presently has a consensus rating of "Moderate Buy" and a consensus price target of $69.83.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.